• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Brazil·Healthcare·BALM3.SA
Share

Baumer S.A. Stocks

R$ 22Last Updated 29.09.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

R$ 48.86M

R$ 22
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Baumer SA engages in the development, manufacture, and sale of hospital, odontology, and health industry solutions and equipment. It operates through the following segments: Orthopedics, Hospital, Genius, and Castanho. The Orthopedics segment manufactures and sells orthopedic implants and instruments. The Hospital segment manufactures and markets equipment for hospitals. pharmaceutical, chemical, cosmetic, and food industry. The Genius segment deals with biomaterials area. The Castanho segment provides equipment for hospital, industrial, and hotel laundry. The company was founded by Manoel Amaral Baumer in July, 1952 and is headquartered in Mogi Mirim, Brazil.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, undervalued

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.10.2026 07:30

The global government bond market experienced its worst quarter since 2024

01.10.2026 06:00

BMW will cut 20% of its management staff. The company is betting on AI

01.10.2026 03:27

Google has unveiled a new AI model. Will it help the company regain its lead in the AI race?

01.10.2026 02:07

A Record Year and a Strong Outlook: Did Micron's Report Confirm the Sustainability of the AI Boom?

01.10.2026 01:11

U.S. Regulator Investigates OpenAI and Anthropic Over AI Safety Concerns — SM

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026